These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Macías J, Liverey Study Investigator Team. J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600 [Abstract] [Full Text] [Related]
30. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. la Porte CJ, Sabo JP, Elgadi M, Cameron DW. Antimicrob Agents Chemother; 2009 Jan; 53(1):162-73. PubMed ID: 19015362 [Abstract] [Full Text] [Related]
34. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524 [Abstract] [Full Text] [Related]